By Editorial Team · Updated 2026-08-28
AOD9604 research centers on a modified 15-amino-acid fragment of human growth hormone (Tyr-hGH177-191), studied for its effects on fat metabolism and cartilage biology. A completed Phase 2b obesity trial failed its primary efficacy endpoint, and as of April 2026 the FDA classifies AOD9604 as a Category 2 bulk drug substance, restricting its use in compounded preparations pending further review. It holds GRAS status for dietary supplement use, but no FDA-approved indication exists for AOD9604 in any form. This article is intended for laboratory research reference only: AOD9604 is not approved for human therapeutic use, and it is not intended to diagnose, treat, cure, or prevent any disease.
What is the origin of aod 9604 peptide?
The aod 9604 peptide originates as a synthetic fragment derived from the C-terminal region of human growth hormone (hGH). Specifically, AOD9604 is the C-terminal fragment (Tyr-hGH177-191) of hGH. This precise molecular structure means the peptide represents only a small, targeted portion of the full growth hormone molecule, which is why HGH fragment 177-191 research treats AOD9604 as a distinct compound from full-length hGH rather than a shorthand equivalent.
Why was this specific fragment chosen for development?
Early stage studies with AOD9604 demonstrated positive activities on fat metabolism. Researchers selected this particular C-terminal fragment because it retains metabolic signaling properties without the broader growth-promoting effects associated with full-length hGH. This selectivity is central to the proposed AOD 9604 mechanism of action, and it makes the peptide a focused subject for AOD 9604 in vitro fat loss studies and other lipid metabolism pathway investigations.
How does this origin differ from full-length growth hormone?
The synthetic origin allows researchers to isolate specific metabolic activities without triggering the broader hormonal cascade associated with intact hGH. This distinction underpins the peptide’s research utility in non-clinical metabolic studies.
What safety data supports aod 9604 peptide?
Available research includes clinical trials and a Phase 2b obesity trial, which together form part of the safety evidence reviewed for this compound. Genotoxicological testing specifically assessed whether the peptide damages DNA.
Was AOD9604 mutagenic in laboratory tests?
An Ames test evaluated the mutagenic potential of AOD9604. This standard bacterial assay screens for compounds that cause genetic mutations. The results showed no mutagenic activity under the test conditions.
Did AOD9604 cause chromosomal damage?
A chromosomal aberration assay in CHO cells tested the peptide’s ability to cause structural damage to chromosomes. This mammalian cell assay provides a more biologically relevant measure of genetic toxicity, and findings like these inform recommended AOD 9604 laboratory handling and storage protocols in non-clinical research settings. The study assessed AOD9604’s mutagenic activity through its capacity to induce chromosomal breaks or rearrangements.
What is the regulatory status of aod 9604 peptide?
The aod 9604 peptide carries a restrictive regulatory status with no approved medical indications. As of April 2026, the FDA classifies AOD9604 as a Category 2 bulk drug substance. This classification restricts compounding pharmacy use pending further FDA review. No FDA-approved indication exists for this peptide.
Why did the Australian TGA reject AOD9604?
The Australian Therapeutic Goods Administration (TGA) rejected an obesity indication for AOD9604. This decision followed a failed Phase 2b clinical trial. The trial did not meet its primary efficacy endpoint for weight loss. This regulatory rejection in Australia aligns with the peptide’s limited approval status globally.
What does FDA Category 2 mean for researchers?
FDA Category 2 designation creates significant barriers for clinical access. Compounding pharmacies face restrictions on using AOD9604 until the FDA completes its review. Researchers should note that no regulatory body has approved AOD9604 for any therapeutic use. This AOD 9604 FDA status disclaimer applies regardless of source: the peptide remains available through unregulated gray-market channels, but these products lack quality oversight and are not intended for human consumption. For broader context on peptide research applications, see our guide on GHK-Cu peptide in laboratory research. Understanding the Peptide Research Applications in Lifestyle Context of peptide studies helps frame experimental design. Additional information on GHK copper peptide benefits provides comparative insight into peptide research methodologies.
Conclusion
In closing, AOD 9604 peptide research continues to evolve as scientists explore its potential mechanisms and applications within metabolic and body composition studies. While early findings show promise, the peptide remains primarily a subject of laboratory investigation, with ongoing work needed to establish efficacy and safety profiles. As research progresses, AOD 9604 represents an intriguing avenue for understanding peptide-based approaches to metabolic function.
Frequently Asked Questions
What is AOD9604?
AOD9604 is a synthetic 15-amino-acid fragment derived from the C-terminal region of human growth hormone (Tyr-hGH177-191). Researchers study it primarily for its effects on fat metabolism and cartilage biology, without the broader growth-promoting effects associated with full-length hGH.
Is AOD9604 approved for human therapeutic use?
No. AOD9604 has no FDA-approved indication in any form. A Phase 2b obesity trial failed to meet its primary efficacy endpoint, and the Australian TGA rejected an obesity indication on that basis. It holds GRAS status for dietary supplement use only, and this article is intended for laboratory research reference, not clinical guidance.
What is the proposed AOD 9604 mechanism of action?
Because AOD9604 isolates the C-terminal fragment of hGH, it is believed to retain metabolic signaling activity linked to fat metabolism while avoiding the broader hormonal cascade triggered by full-length growth hormone. This selectivity is what makes it a focused subject for in vitro fat loss and lipid metabolism pathway studies.
What does the current safety and genotoxicity data show?
Available non-clinical testing includes an Ames test, which found no mutagenic activity, and a chromosomal aberration assay in CHO cells, which assessed the peptide’s potential to cause chromosomal breaks or rearrangements. These findings inform laboratory handling and storage protocols but do not establish a clinical safety profile.
What is AOD9604’s current regulatory status?
As of April 2026, the FDA classifies AOD9604 as a Category 2 bulk drug substance, which restricts its use in compounded preparations pending further review. No regulatory body has approved it for therapeutic use, and any product sold outside regulated research channels lacks quality oversight and is not intended for human consumption.
This article is for informational and research purposes only. All products discussed are sold strictly for laboratory and research use, not for human or veterinary use, consumption, or diagnostic application.
